Article Text

PDF
Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women
  1. K Y-K Chan1,
  2. W Liu1,2,
  3. J-R Long3,
  4. S-P Yip4,
  5. S-Y Chan1,5,
  6. X-O Shu3,
  7. D T-T Chua5,
  8. A N-Y Cheung1,
  9. J C-Y Ching1,
  10. H Cai3,
  11. G K-H Au5,
  12. M Chan6,
  13. W Foo7,
  14. H Y-S Ngan8,
  15. Y-T Gao9,
  16. E S-W Ngan10,
  17. M-M Garcia-Barceló10,
  18. Wei Zheng3,
  19. U-S Khoo1
  1. 1
    Department of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China
  2. 2
    Department of Pathology, First Affiliated Hospital of Soochow University, Suzhou
  3. 3
    Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, USA
  4. 4
    Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong SAR, China
  5. 5
    Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China
  6. 6
    Department of Surgery, Kwong Wah Hospital, Hong Kong SAR, China
  7. 7
    Department of Clinical Oncology, Queen Elisabeth Hospital, Hong Kong SAR, China
  8. 8
    Department of Obstetrics and Gynecology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China
  9. 9
    Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China
  10. 10
    Department of Surgery, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China
  1. Dr U-S Khoo, Room 324, 3/F, University Pathology Building, Department of Pathology, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China; uskhoo{at}pathology.hku.hk

Abstract

Background: The BRCA1 gene is an important breast-cancer susceptibility gene. Promoter polymorphisms can alter the binding affinity of transcription factors, changing transcriptional activity and may affect susceptibility to disease.

Methods and Results: Using direct sequencing of the BRCA1 promoter region, we identified four polymorphisms c.-2804T→C (rs799908:T→C), c.-2265C→T (rs11655505:C→T), c.-2004A→G (rs799906:A→G) and c.-1896(ACA)1→(ACA)2 (rs8176071:(ACA)1→(ACA)2) present in Hong Kong Chinese. Each polymorphism was studied independently and in combination by functional assays. Although all four variants significantly altered promoter activity, the c.-2265T allele had stronger binding than the C allele, and the most common mutant haplotype, which contains the c.-2265T allele, increased promoter activity by 70%. Risk association first tested in Hong Kong Chinese women with breast cancer and age-matched controls and replicated in a large population-based study of Shanghai Chinese, together totalling >3000 participants, showed that carriers of the c.-2265T allele had a reduced risk for breast cancer (combined odd ratio (OR) = 0.80, 95% CI 0.69 to 0.93; p = 0.003) which was more evident among women aged ⩾45 years at first diagnosis of breast cancer and without a family history of breast cancer (combined OR = 0.75, 95% CI 0.61 to 0.91; p = 0.004). The most common haplotype containing the c.-2265T allele also showed significant risk association for women aged ⩾45 years without a family history of breast cancer (OR = 0.64, 95% CI 0.46 to 0.89; p = 0.008).

Conclusion: This comprehensive study of BRCA1 promoter polymorphisms found four variants that altered promoter activity and with the most significant contribution from c.-2265C→T, which could affect susceptibility to breast cancer in the Chinese population. Its significance in other populations remains to be investigated.

Statistics from Altmetric.com

Footnotes

  • ▸ Supplementary tables and figure are published online only at http://jmg.bmj.com/content/vol46/issue1

  • The first two authors contributed equally to this work

  • Funding: This study was funded by the Research Grant Council, Hong Kong SAR, China, (project code HKU 7520/05M) and the Committee on Research and Conference Grants from the University of Hong Kong (project code 200711159018). The Shanghai Breast Cancer Study is supported by RO1CA64277 and RO1CA90899 from the National Cancer Institute.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.